Literature DB >> 17715327

Improved efficacy of a licensed acellular pertussis vaccine, reformulated in an adjuvant emulsion of liposomes in oil, in a murine model.

Marc Mansour1, Robert G Brown, Annette Morris, Bruce Smith, Scott A Halperin.   

Abstract

The immunogenicities and efficacies of a licensed diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine and the same vaccine formulated in a liposome/oil emulsion adjuvant were compared in a mouse model of pertussis respiratory infection. A single dose of the liposome/oil emulsion-adjuvanted vaccine produced significantly higher antibody levels than one dose of the licensed vaccine and protected mice from Bordetella pertussis infection with an efficacy equivalent to that of three doses of the licensed vaccine.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17715327      PMCID： PMC2168125          DOI： 10.1128/CVI.00143-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  9 in total

Review 1.  Immunity to Bordetella pertussis.

Authors:  K H Mills
Journal:  Microbes Infect       Date:  2001-07       Impact factor: 2.700

Review 2.  Ethical issues for vaccines and immunization.

Authors:  Jeffrey B Ulmer; Margaret A Liu
Journal:  Nat Rev Immunol       Date:  2002-04       Impact factor: 53.106

3.  Pertussis vaccines.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  1999-05-07

4.  Temporal trends in antibody production in captive grey, harp and hooded seals to a single administration immunocontraceptive vaccine.

Authors:  R G Brown; W D Bowen; J D Eddington; W C Kimmins; M Mezei; J L Parsons; B Pohajdak
Journal:  J Reprod Immunol       Date:  1997-11-01       Impact factor: 4.054

Review 5.  An adolescent and adult formulation combined tetanus, diphtheria and five-component pertussis vaccine.

Authors:  Michael E Pichichero; Lisa M DeTora; David R Johnson
Journal:  Expert Rev Vaccines       Date:  2006-04       Impact factor: 5.217

6.  Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion.

Authors:  Pirouz Daftarian; Marc Mansour; Anita C Benoit; Bill Pohajdak; David W Hoskin; Robert G Brown; W Martin Kast
Journal:  Vaccine       Date:  2006-04-18       Impact factor: 3.641

7.  Experimental respiratory infection with Bordetella pertussis in mice: comparison of two methods.

Authors:  S A Halperin; S A Heifetz; A Kasina
Journal:  Clin Invest Med       Date:  1988-08       Impact factor: 0.825

8.  Pertussis--United States, January 1992-June 1995.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1995-07-21       Impact factor: 17.586

9.  Mucosal immunization with a genetically engineered pertussis toxin S1 fragment-cholera toxin subunit B chimeric protein.

Authors:  Song F Lee; Scott A Halperin; Danny F Salloum; Ann MacMillan; Annette Morris
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.